| Literature DB >> 33688185 |
Hossein Zare1,2, Sepideh Ahmadi3,4, Amir Ghasemi5, Mohammad Ghanbari6, Navid Rabiee7, Mojtaba Bagherzadeh7, Mahdi Karimi8,9,10,11, Thomas J Webster12, Michael R Hamblin13, Ebrahim Mostafavi12,14,15.
Abstract
The unique properties of carbon nanotubes (CNTs) (such as their high surface to volume ratios, enhanced conductivity and strength, biocompatibility, ease of functionalization, optical properties, etc.) have led to their consideration to serve as novel drug and gene delivery carriers. CNTs are effectively taken up by many different cell types through several mechanisms. CNTs have acted as carriers of anticancer molecules (including docetaxel (DTX), doxorubicin (DOX), methotrexate (MTX), paclitaxel (PTX), and gemcitabine (GEM)), anti-inflammatory drugs, osteogenic dexamethasone (DEX) steroids, etc. In addition, the unique optical properties of CNTs have led to their use in a number of platforms for improved photo-therapy. Further, the easy surface functionalization of CNTs has prompted their use to deliver different genes, such as plasmid DNA (PDNA), micro-RNA (miRNA), and small interfering RNA (siRNA) as gene delivery vectors for various diseases such as cancers. However, despite all of these promises, the most important continuous concerns raised by scientists reside in CNT nanotoxicology and the environmental effects of CNTs, mostly because of their non-biodegradable state. Despite a lack of widespread FDA approval, CNTs have been studied for decades and plenty of in vivo and in vitro reports have been published, which are reviewed here. Lastly, this review covers the future research necessary for the field of CNT medicine to grow even further.Entities:
Keywords: carbon nanotube; drug delivery; gene delivery; precision medicine
Year: 2021 PMID: 33688185 PMCID: PMC7936533 DOI: 10.2147/IJN.S299448
Source DB: PubMed Journal: Int J Nanomedicine ISSN: 1176-9114
Different Medical Applications of CNTs
| Application | Description | Ref. |
|---|---|---|
| Bio-sensing | CNTs show special optical, mechanical, and electronic properties that make them attractive candidate materials for the manufacture of optical and electrochemical biosensors | [ |
| Bio-imaging | Features such as high photostability and absence of quenching, make CNTs suitable for bio-imaging applications | [ |
| Photo-Thermal Therapy | The ability of CNTs to convert near infrared radiation (NIR) into heat is well known | [ |
| Tissue Engineering | CNTs are good materials for tissue engineering due to their biocompatibility, rigidity, mimicking of natural tissue nanofibers, stimulating the adhesion and proliferation of cells and ability to form strong 3D architectures | [ |
| Drug/gene Delivery | CNTs have been considered as carriers for drug/gene delivery due to their high surface area, multifunctional surface chemistry, lack of immunogenicity and unique needle-like shapes with an ability to easily penetrate cell membranes | [ |
| Lab-on-a-chip devices | Lab-on-a-chip (LOC) devices are miniaturized systems in which tiny volumes of fluids flowing in various channels are designed for purposes such as drug screening, cell growth, and disease models. In this regard, CNTs have been used as membrane channels, sensors and channel walls in LOC devices. | [ |
Summary of Articles on CNT Cellular Internalization Mechanisms
| Types of Carbon Nanotubes | Length (L)/Diameter (D) | Surface-Modified Complex | Cell Types | Mechanisms | Ref. |
|---|---|---|---|---|---|
| SWCNTs | L: >1 µm | Pluronic- F108:CNT | Macrophage cells | Phagocytosis | [ |
| SWCNTs | 30–400 nm | – | Murine macrophage RAW264.7 cells | Phagocytosis | [ |
| MWCNT | L: 453.5 ± 6.2 | C6-CNTPC | A549 cells | Phagocytosis | [ |
| SWCNTs | L:195–630 nm | – | Murine macrophage cells | Macropinocytosis | [ |
| MWCNTs | L: >300 nm | p(4VP)-MWCNTs | TT1 cells | Macropinocytosis | [ |
| SWCNTs | L: <500 nm/D: 1–2 nm | AO–SWCNTs | Hela cells | Clathrin-mediated endocytosis | [ |
| MWCNTs | L:10 µm/D: 60 nm | – | BEAS-2B cells, HBEpCs | Clathrin- and caveolae-mediated endocytosis | [ |
| SWNTs | L: 0.05–0.2 μm/<1 μm | SWNT-DNA, SWNT- proteins | HeLa cell | Clathrin-dependent endocytosis | [ |
| MWCNTs | D: ~200 nm | Oxidized -MWCNTs | Caco-2 cell | Clathrin-dependent endocytosis | [ |
| CNTs | L: 250–400 nm | PEG-CNT-ABT737 nanodrug | A549 non-small cell lung cancer cells | Clathrin-mediated endocytosis | [ |
| SWNTs | L: 100–200 nm/D: 1–3 nm | FA-SWNTs | HepG2 cells | Folate receptor mediated endocytosis | [ |
| SWNTs | L:50–100 nm/D: 1–3 nm | FA- SWNTs | HepG2 cells | Folate receptor mediated endocytosis | [ |
| MWCNTs | L: 3 lm to 10 lm/D: 50 nm – 300 nm | – | Human neonatal epidermal keratinocytes (HEK) | Lectin receptor mediated endocytic pathway | [ |
| SWCNTs | L: 50–200 nm/D: 1–3 nm | FA-SWCNTs | HepG2 cells | Passive diffusion for 50 nm or less SWNTs | [ |
| MWCNTs | D: 20–30 nm | FITC- MWCNTs | Plant cells | Passive diffusion | [ |
Abbreviations: HBEpCs, human bronchial epithelial cells; FA, folate acid; C6-CNTPC, coumarin-6 loaded TPGS conjugated MWCNT.
Advantages and Disadvantages of Various CNT Cellular Internalization Mechanisms
| Mechanism | Positive Characteristics | Negative Characteristics | Ref. |
|---|---|---|---|
| Passive diffusion | Rapid diffusion of CNTs across the cell lipid membrane in a non-invasive manner | Non-specific | [ |
| Phagocytosis | Ability to uptake large particles (~ 1 μm) Specific cell-type targeting | Need a coating on CNTs to enhance recognition and uptake by phagocytes ○ Degradation of cargo by lysosomes | [ |
| Macropinocytosis | Ability to uptake large particles Uptake of cargo through large vacuoles | Non-specific | [ |
| Clathrin-dependent endocytosis | Size-dependent regulation of particle internalization | Degradation of cargo by lysosomes | [ |
| Caveolae-mediated endocytosis | Specific receptors Bypass the endo-lysosomes Enhance the efficiency of transfection | Membrane structure dependent | [ |
Functionalized CNTs and Their Effect on Solubility, Toxicity, and Effective Cellular Internalization Mechanisms
| Functionalized-CNTs | Cell Types | Major Results | Ref. | |
|---|---|---|---|---|
| SPAN-MWCNT | – | Weaker π-π bonds between CNTs and SPAN, and high solubility | [ | |
| Pl-PEG-SWCNT | Jurkat cell line | Increase in aqueous solubility by non-covalent functionalization of SWCNTs | [ | |
| MWCNT-FITC | RAW 264.7 murine macrophages - A459 human lung carcinoma cells | Surface modification of CNTs can facilitate effective cellular uptake | [ | |
| Vitamin E TPGS-MWCNT (C6-CNTPC) | A549 cells | Increase in anticancer properties of DTX according to the phagocytosis mechanism of C6-CNTPC | [ | |
| PEGylated CNT-ABT737 | A549 non-small cell lung cancer cells | Increase mitochondrial targeting with early endosomal escape, increase accumulation of complex in mitochondria and effective released drug | [ | |
| SWCNT-PEG-THFF | D54MG-EGFP cells | This functional group protects D54MG-EGFP cells while the SWCNT backbone is harmful for these cells | [ | |
| CD-SWCNTs | MCF-7 and HeLa cells | Decreases the toxicity of CNTs and adverse side effects as a FMN drug delivery carrier | [ | |
| FA- MWCNTs | HeLa cells | FA- MWCNTs are non-toxic to HeLa cells with cell viabilities more than 90% | [ | |
| CH−β-GP–CNT hybrid hydrogels | 3T3 cells | Hydrogels containing CNTs (0.1%) showed no-toxicity in 3T3 cells with high cell viability | [ | |
| SWCNT−PB (SPB) | 293T and A549 cells | SPB showed low cytotoxicity to both cell lines and more than an 80% cell viability at a high concentration of 50 μg mL−1 | [ | |
| SWNT-PEG-PEI- AS1411 aptamer | L929 and AGS cells | This functionalized nanoplex showed low cytotoxicity in cells | [ | |
| SWNT-PEI conjugates | N2A murine neuroblastoma cells | None of the SWNT-PEI110, and SWNT-PEI110 carriers had major cytotoxicity except SWNT-acyl-PEI1.8 (S1.8), SWNT-acyl-PEI10 (AC10) and SWNT-acyl-PEI25 (AC25) | [ |
Abbreviations: Pl-PEG, phospholipid-PEG; FA, folic acid; CH, chitosan; β-GP, β-glycerophosphate; PB, PEI−betaine; SPAN, sulfonated polyaniline; FMN, formononetin.
Figure 1This scheme shows how DTX was conjugated to MWCNTs.
Figure 2Schematic illustration of DOX-SPBB-siRNA nanocarriers for treating lung cancer cells.
Other Examples of CNTs Used for the Delivery of Molecules
| CNTs | Molecules | Functional Group | Particle Size | Release Control | In vitro/in vivo | Ref. |
|---|---|---|---|---|---|---|
| SWCNTs | Carnosine dipeptide | Modified with PEG at the lysine residues via amide bonds | – | – | – | [ |
| SWNTs | DOX | Modified with oxidative acid and PEG-g-PEI | Diameter 1–2 nm, length 1–3 nm, SSA 380 m2/g | Acidic pH | In vitro | [ |
| MWCNTs | DOX | Functionalized with (TAT)-chitosan (MWCNTs-TC) | – | – | In vivo, in vitro | [ |
| SWCNT | DTX | Functionalized with iron oxide NPs and coated by PLA co-mPEG micelles | ~ 15–50nm | External magnetic fields | In vivo, in vitro | [ |
| SWCNT | EGFP (nEGFP) | Functionalized with streptavidin | ~ 200 nm in length | Light-responsive | In vivo, in vitro | [ |
| MWCNT | Zolpidem (ZM) | Modified with D-glucose (Gl) | Diameter of MWCNTCOOH 10 nm, 27 nm in MWCNT-Gl | - | In vitro | [ |
| SWNTs | DOX | Non-covalently functionalized with PL-PEG | ~ 1 nm and ~1.2 nm inner and outer diameters, 50–200 nm PEG-coated SWNTs | NIR irradiation | In vitro | [ |
| MWCNT | DTX | Chitosan-folate (CHI-FA) conjugated MWCNT | ~ 230 to 483 nm in length | – | In vivo, in vitro | [ |
| MWCNTs | Antigenic protein (OVA) | Modified with lentinan | 9–10 nm in diameter, 1–2 μm in length | – | In vivo, in vitro | [ |
Figure 3In vivo biodistribution of fluorescent-labeled rCNT (A1 and A2) and fCNT (B1 and B2) in mice.
Cell Viability and in vivo Toxicity Results for Various Concentrations of Functionalized-CNTs
| Types of Functionalized CNTs | In vito/in vivo Model | Cell Viability/in vivo Results | Concentration of CNTs (μg/mL) | Ref. |
|---|---|---|---|---|
| FA- MWCNTs | HeLa cells | >90% | – | [ |
| MWCNT-COOH | HEK 293 cells | 91.96/47.78% | 25 μg/mL/300 μg/mL | [ |
| MWCNT-COOH | Zebra fish embryos | Non-significant decrease in survival rate | – | [ |
| PLL-CNT@PDA film, PLL-CNT-COOH film | RAW264.7 cells | No viability changes in cells | – | [ |
| SWCNT−PB (SPB) | 293T and A549 cells | >80% | 50 μg/mL | [ |
| Tangled oxidized multi-walled CNTs (t-ox-MWCNTs) | Wistar strain rat | Low toxicity and long-term biopersistence of the t-ox-MWCNTs in vivo | <100 μg | [ |
| PEGylated SWNT | 8–12 to week-old nude mice | Toxicity of high doses was not observed in nude mice | 151 mg of PEG-SWNT | [ |